20th January 2017 – Today Aravax established a collaboration with the prestigious Benaroya Research Institute in Seattle. The research group led by Erik Wambre (PhD) will work with Aravax on research into immunological responses to Aravax’s therapy, PVX108.
Melbourne, Australia, 23 November 2015: Two new Victorian medical technology companies have been awarded $9 million in venture capital funding to develop novel treatments for heart failure and peanut allergies.
The companies, Cardiora Pty Ltd and Aravax Pty Ltd -- spun...
